Echocardiographic Follow-up of Perinatally HIV-infected Children and Adolescents
- 11 March 2020
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 39 (6) , 526-532
Abstract
Background: The effects of HIV and antiretroviral therapy on cardiovascular system of perinatally infected children throughout their development are not fully understood. Objectives: To determine the prevalence of cardiac abnormalities in a retrospective cohort of perinatally HIV-infected patients and to investigate associations between echocardiographic and clinical data during their follow-up. Methods: Review of medical records and echocardiogram reports of 148 perinatally HIV-infected patients between January 1991 and December 2015. Results: Four hundred and eighty echocardiograms were analyzed and 46 (31%) patients showed cardiac abnormalities, frequently subclinical and transient. Nadir CD4 count was higher in patients with consistently normal echocardiogram: 263 (4–1480) versus 202 (5–1746) cells/μL, P = 0.021. Right ventricular (RV) dilation was detected in 18.9%, left ventricular (LV) dilation in 21.6%, septal hypertrophy in 12.2%, LV posterior wall hypertrophy in 6%, LV systolic dysfunction in 8% and pulmonary hypertension in 8.7% of patients. Opportunistic infections were associated with RV dilation [odds ratio (OR = 4.34; 1.78–10.53; P < 0.01)], pulmonary hypertension (OR = 8.78; 2.80–27.51; P < 0.01) and LV systolic dysfunction (OR = 5.38; 1.55–18.71; P < 0.01). Longer duration of highly active antiretroviral therapy was associated with reduced risk of LV dilation (OR = 0.91; 0.85–0.97; P < 0.01) and systolic dysfunction (OR = 0.71; 0.59–0.85; P < 0.01). Protease inhibitors use was associated with reduced risk of RV dilation (OR = 0.54; 0.30–0.97; P < 0.05), LV dilation (OR = 0.35; 0.21–0.60; P < 0.01) and LV systolic dysfunction (OR = 0.07; 0.02–0.31; P < 0.01). Higher CD4 count was associated with lower risk of LV systolic dysfunction (OR = 0.82; 0.69–0.98; P < 0.05). Conclusions: Echocardiograms identified cardiac abnormalities among children with perinatally acquired HIV infection, and data suggest that immunologic status and therapeutic strategies throughout development can influence cardiac disease burden in this population.Keywords
This publication has 35 references indexed in Scilit:
- The Causes of HIV-Associated Cardiomyopathy: A Tale of Two WorldsBioMed Research International, 2016
- Declining Incidence of Systolic Left Ventricular Dysfunction in Human Immunodeficiency Virus–Infected Individuals Treated With Highly Active Antiretroviral TherapyThe American Journal of Cardiology, 2016
- Effects of paediatric HIV infection on childhood vasculatureEuropean Heart Journal, 2016
- Evidence of increased blood pressure and hypertension risk among people living with HIV on antiretroviral therapy: a systematic review with meta-analysisJournal of Human Hypertension, 2015
- Human Immunodeficiency Virus and Heart Failure in Low- and Middle-Income CountriesJACC: Heart Failure, 2015
- Cardiac effects in perinatally HIV‐infected and HIV‐exposed but uninfected children and adolescents: a view from the United States of AmericaJournal of the International AIDS Society, 2013
- Association of Hypercholesterolemia Incidence With Antiretroviral Treatment, Including Protease Inhibitors, Among Perinatally HIV-Infected ChildrenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
- Cardiomyopathy with Mitochondrial Damage Associated with Nucleoside Reverse-Transcriptase InhibitorsNew England Journal of Medicine, 2002
- Use of HIV Protease Inhibitors Is Associated With Left Ventricular Morphologic Changes and Diastolic DysfunctionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
- Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy?Current Opinion in Infectious Diseases, 2000